Pharming Group N.V. (PHAR) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Farming Q2 and first half 2025 financial results conference call and webcast. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one and one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Fabrice Chiracchi. Please go ahead. Thank you, operator, and good morning or good afternoon, everyone, and welcome to our Q2 2025 earning call. So I'm Fabrice Chiracchi, the CEO of Farming, and I'll be joined on this call today by Steve Thor, our Chief Commercial Officer, and Anurag Relin, our Chief Medical Officer. Next slide. So, on this call, we will be making forward-looking statements that are based upon our current insights and plans. As you know, these may differ from future results. Next slide. Next slide. So, as you saw in our press release earlier today, farming delivered a very strong quarter. Total revenues grew by 26% in the second quarter of 2025 versus the same quarter last year. And we delivered meaningful operating profits of $12.9 million compared to a loss in the previous year. This number excludes about $2 million in non-recurring Abliva acquisition-related expenses. Our strong top-line growth was fueled by the continued significant growth of Reconnect, 28% year-on-year, and the further acceleration of patient uptake on joint jobs, with the increase of patients on drugs in the first half of 2025 already surpassing the total increase for ...